Libra Review | Choose Better

After getting grossed out by witnessing open coronary heart surgical procedure in 4th grade, David Ehrlich needed nothing to do with medication. So it’s considerably ironic that he grew to become CEO of Aktana , an clever buyer engagement firm serving the healthcare trade. David stayed at school manner too lengthy, lastly dropping out of the economics PhD program at Harvard earlier than making a profession at McKinsey after which at start-ups. On this episode of the HealthBiz podcast, David retraces his path and shares the advances Aktana is making in utilizing contextual intelligence to information industrial selections in an omnichannel surroundings. David lately learn Klara and the Sun , a Japanese novel about a synthetic buddy with unbelievable observational skills, concurrently empowered and restricted by its synthetic intelligence. Well being Enterprise Group is a technique consulting agency that helps corporations like Aktana develop strong development plans. ...

Marc Leighton, VP of Product at Florence Healthcare Prior to COVID, major technological transformation initiatives were already underway at many clinical trial sites, sponsors, and contract research organizations (CROs.) But the move to decentralized trials accelerated dramatically in 2020 and 2021–and it’s not slowing down.  Survey data from WCG Avoca shows that research sites and sponsors expect 89% of clinical trials to qualify as a hybrid, with a mix of decentralized technology and in-person visits.  But what will these decentralized clinical trials (DCTs) look like? I’d like to share some bold predictions for DCTs in 2022 (and beyond!):  Sites and sponsors shouldn’t be locked into a zero-sum game against one another. In 2022, they’ll be unified by complementary technology and the common purpose of getting cures to market.  By the end of the year, I expect the majority of sites will have an electronic Investigator Site File (eISF) and electronic informed consent (eConsent)....